{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:59:10Z","timestamp":1790665150188,"version":"4.1.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.03117","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T08:37:33Z","timestamp":1547455053000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Inducible IFN-\u03b3 Expression for MHC-I Upregulation in Devil Facial Tumor Cells"],"prefix":"10.3389","volume":"9","author":[{"given":"Chrissie E. B.","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Bruce","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Flies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/439549a","article-title":"Allograft theory: transmission of devil facial-tumour disease","volume":"439","author":"Pearse","year":"2006","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1073\/pnas.1519691113","article-title":"A second transmissible cancer in Tasmanian devils","volume":"113","author":"Pye","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1111\/1365-2664.13088","article-title":"Density trends and demographic signals uncover the long-term impact of transmissible cancer in Tasmanian devils","volume":"55","author":"Lazenby","year":"2018","journal-title":"J Appl Ecol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"20160553","DOI":"10.1098\/rsbl.2016.0553","article-title":"Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils","volume":"12","author":"Pye","year":"2016","journal-title":"Biol Lett."},{"key":"B5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41598-017-00439-7","article-title":"Variants in the host genome may inhibit tumour growth in devil facial tumours: evidence from genome-wide association","volume":"7","author":"Wright","year":"2017","journal-title":"Sci Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1073\/pnas.1219920110","article-title":"Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer","volume":"110","author":"Siddle","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065133","article-title":"Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease","author":"Phalen","year":"2013","journal-title":"PLoS ONE"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024475","article-title":"Natural killer cell mediated cytotoxic responses in the Tasmanian devil","author":"Brown","year":"2011","journal-title":"PLoS ONE"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1016\/j.vaccine.2015.01.039","article-title":"Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations","volume":"33","author":"Kreiss","year":"2015","journal-title":"Vaccine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e35314","DOI":"10.7554\/eLife.35314","article-title":"The newly-arisen Devil facial tumour disease 2 (DFT2) reveals a mechanism for the emergence of a contagious cancer","volume":"7","author":"Caldwell","year":"2018","journal-title":"Elife"},{"key":"B11","doi-asserted-by":"publisher","first-page":"43827","DOI":"10.1038\/srep43827","article-title":"Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils","volume":"7","author":"Tovar","year":"2017","journal-title":"Sci Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fimmu.2018.00259","article-title":"Immunization strategies producing a humoral IgG immune response against devil facial tumor disease in the majority of tasmanian devils destined for wild release","volume":"9","author":"Pye","year":"2018","journal-title":"Front Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/infdis\/jir436","article-title":"Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children","volume":"204","author":"Hoft","year":"2011","journal-title":"J Infect Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/infdis\/158.1.160","article-title":"Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines","volume":"158","author":"Zhaori","year":"1988","journal-title":"J Infect Dis."},{"key":"B15","volume-title":"Global Commission for the Certification of Smallpox Eradication & World Health Organization. The Global Eradication of Smallpox : Final Report of the Global Commission for the Certification of Smallpox Eradication","author":"World","year":"1980"},{"key":"B16","first-page":"895","article-title":"Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine","volume":"59","author":"Poland","year":"1981","journal-title":"Bull World Health Organ."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJM198405313102201","article-title":"Live attenuated varicella virus vaccine \u2014 Efficacy trial in healthy children","volume":"310","author":"Weibel","year":"1984","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3389\/fimmu.2016.00581","article-title":"PD-L1 is not constitutively expressed on tasmanian devil facial tumor cells but is strongly upregulated in response to IFN-\u03b3 and can be expressed in the tumor microenvironment","volume":"7","author":"Flies","year":"2016","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cells activation","volume":"25","author":"Thibult","year":"2012","journal-title":"Int Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1084\/jem.170.5.1595","article-title":"Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells","volume":"170","author":"Hansson","year":"1989","journal-title":"J Exp Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"7673","DOI":"10.1073\/pnas.93.15.7673","article-title":"Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma","volume":"93","author":"Bromberg","year":"1996","journal-title":"Proc Natl Acad Sci USA."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1002\/j.1460-2075.1996.tb00760.x","article-title":"Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas\/APO-1 and TNF-alpha","volume":"15","author":"Deiss","year":"1996","journal-title":"EMBO J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1038\/sj.onc.1202217","article-title":"IFN\u03b3 inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1\/CIP1","volume":"17","author":"Kominsky","year":"1998","journal-title":"Oncogene"},{"key":"B26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/gut.49.2.251","article-title":"Interferon \u03b3 inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis","volume":"49","author":"Detjen","year":"2001","journal-title":"Gut"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/sj.onc.1205255","article-title":"IFN\u03b3 sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway","volume":"21","author":"Fulda","year":"2002","journal-title":"Oncogene"},{"key":"B28","volume-title":"Using Interferon-Gamma Signalling in DFTD Cells to Refine Their Immunogenicity for Use in a Protective Vaccine","author":"Rumley","year":"2015"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1073\/pnas.89.12.5547","article-title":"Tight control of gene expression in mammalian cells by tetracycline-responsive promoters","volume":"89","author":"Gossen","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"B30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/biot.201400821","article-title":"Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines","volume":"10","author":"Kowarz","year":"2015","journal-title":"Biotechnol J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/ng.343","article-title":"Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates","volume":"41","author":"M\u00e1t\u00e9s","year":"2009","journal-title":"Nat Genet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(87)90480-6","article-title":"Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation","volume":"329","author":"Levine","year":"1987","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJM199411243312101","article-title":"The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program","volume":"331","author":"Peltola","year":"1994","journal-title":"N Engl J Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1586\/14760584.3.6.643","article-title":"Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine","volume":"3","author":"Belshe","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"B35","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","article-title":"B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells","volume":"111","author":"Azuma","year":"2008","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"16025","DOI":"10.1038\/sigtrans.2016.25","article-title":"A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity","volume":"1","author":"Tian","year":"2016","journal-title":"Signal Transduct Target Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.03117\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T08:37:37Z","timestamp":1547455057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.03117\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2018.03117"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.03117","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]},"article-number":"3117"}}